Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27300499 | 0.81 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL26711864 | 0.71 | NPSR1 (0.43) | KCNH2 | |
| SCHEMBL22840004 | 0.71 | LMNA (0.39) | — | |
| SCHEMBL25800424 | 0.70 | CCND1 (0.36) | KCNH2 | |
| SCHEMBL27401573 | 0.67 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL10256676 | 0.66 | THRB (0.39) | — | |
| SCHEMBL26711790 | 0.65 | GABRA1 (0.36) | KCNH2 | |
| SCHEMBL12173270 | 0.64 | EIF4A3 (0.42) | — | |
| SCHEMBL24819396 | 0.64 | HRH3 (0.38) | — | |
| SCHEMBL25702110 | 0.64 | KCNH2 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | KCNH2 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.